We hypothesize that changes in CF may affect the rest of the outcomes and, in our opinion, IMT at 70% of the MIP will significantly improve CF.<h4>Clinical implications</h4>If the expected benefits are observed, the results may recommend including IMT as a fundamental component of a CRP in our study population.<h4>Trial registration number</h4>Registered prospectively at ClinicalTrials.gov (NCT06681740) Version 4. The gene discussed is CRP; the disease is cystic fibrosis.